RCS - Itaconix PLC - SPARX collaboration with Bonals Technologies

ItaconixAnnouncement

14/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241114:nRSN1555Ma&default-theme=true

RNS Number : 1555M  Itaconix PLC  14 November 2024

For release on Reach: 14 November
2024

Itaconix plc

("Itaconix", the "Company" or the "Group")

SPARX collaboration agreement with Bonals Technologies

Itaconix plc (AIM: ITX) (OTCQB: ITXXF), a leading innovator in plant-based
specialty polymers used to decarbonise everyday consumer products, today
announces a collaboration agreement with Bonals Technologies ("Bonals") under
the Company's SPARX program to speed the introduction of safer, better
performing, and more sustainable unit dose detergent tablets in the United
States and Canada.

Bonals is based in Saint-Just-Saint-Rambert, France and produces tableting
equipment that is used by leading detergent tablet brands and contract
manufacturers in Europe. Under the agreement, Itaconix will work with Bonals
and leading North America detergent suppliers on new generations of detergents
that seek to leverage the synergistic benefits of Itaconix tablet formulations
produced on Bonals equipment.

Announced in October, Itaconix's SPARX program integrates collaboration
efforts between advanced specialty ingredients companies, contract
manufacturers, and purpose-driven brands to introduce new innovations in
certain consumer product categories. The program has a goal of having brands
release at least ten new products generated from these collaborative efforts
by the end of 2025.

Philippe Taste, President of Bonals Technologies, commented:

"We see increasing opportunities outside of Europe for the high-performing
tablets produced with our equipment. Based on work with our customers in
Europe, we recognised that Itaconix is at the forefront of formulating new
generations of unit dose detergents that fit closely with the unique
advantages of our tableting capabilities. We are excited to collaborate with
Itaconix to pursue new opportunities together in North America.

Dr Jim Gordon, Global Director, Cleaning & Hygiene at Itaconix, commented:

"We are demonstrating in Europe that formulations using our Itaconix
ingredients are contributing to the competitive success of major European
contract detergent tableters. Interest in tablets is increasing in North
America based on the advantages they have for efficient unit dosing, without
the use of plastic wrapping. By working with Bonals and current North American
contract manufacturers in our SPARX program, we aim to enable North American
production of detergent tablets that have levels of in-wash performance found
in Europe."

- Ends -

Enquiries:

Itaconix plc
 
+1 603 775 4400

John R. Shaw / Laura Denner

Rosewood
 
+44 (0) 207 653 8704

Financial PR

John West / Llew Angus

Canaccord Genuity
 
+44 (0) 7523 8000

Nominated Adviser and Broker

Adam James / Harry Pardoe

 

About Itaconix

Itaconix uses its proprietary plant-based polymer technology platform to
produce and sell specialty ingredients that improve the safety, performance,
and sustainability of consumer products. The Company's current ingredients are
enabling and leading new generations of products in detergents, hygiene, and
hair care. Itaconix's products contribute to the global low carbon economy.

https://itaconix.com/ (https://itaconix.com/)

About Bonals Technologies

Bonals Technologies is a tableting technology provider serving customers
worldwide. With 1000+ machines currently producing, the company developed
strong partnerships with leading detergent tablet brands and contract
manufacturers in Europe and Asia thanks to innovative and ecological solutions
dedicated to homecare, laundry care and chemicals.

https://www.bonals.com/ (https://www.bonals.com/)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABRBDBSDBDGSX